Abstract
Since its inception 20 years ago, the animal pharming industry has promoted transgenic animals as a cost-effective method of biopharmaceutical production. However, it took until 2006 for the first therapeutic product to gain regulatory approval. This was an important milestone, but scepticism still abounds. Can pharming regain investor confidence, and will society accept transgenic livestock as a production method? There is some cause for optimism, biopharmaceuticals are a large, expanding market and animal pharming has already made considerable strides. A novel production platform has been established, groundbreaking technologies developed, a necessary regulatory framework put in place. Nevertheless, despite cost advantages, pharming has become a niche production method and its long term success may depend on products unique to transgenic animals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Almagro JC, Fransson J (2008) Humanization of antibodies. Front Biosci 13:1619–1633
Anderson C (1991) “AIDSgate”—a chronology. Nature 353:197
Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I et al (2000) Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 55:1075–1081
Brüggemann M, Caskey HM, Teale C, Waldmann H, Williams GT, Surani MA et al (1989) A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc Natl Acad Sci USA 86:6709–6713. doi:10.1073/pnas.86.17.6709
Butler M (2005) Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals. Appl Microbiol Biotechnol 68:283–291. doi:10.1007/s00253-005-1980-8
Clark AJ (1998) The mammary gland as a bioreactor: expression, processing, and production of recombinant proteins. J Mammary Gland Biol Neoplasia 3:337–350. doi:10.1023/A:1018723712996
Clark AJ, Simons P, Wilmut I, Lathe R (1987) Pharmaceuticals from transgenic livestock. Trends Biotechnol 5:20–24. doi:10.1016/0167-7799(87)90076-X
Collick A, Drew J, Penberth J, Bois P, Luckett J, Scaerou F et al (1996) Instability of long inverted repeats within mouse transgenes. EMBO J 15:1163–1171
Covarrubias L, Nishida Y, Mintz B (1986) Early postimplantation embryo lethality due to DNA rearrangements in a transgenic mouse strain. Proc Natl Acad Sci USA 83:6020–6024. doi:10.1073/pnas.83.16.6020
Dyck MK, Lacroix D, Pothier F, Sirard MA (2003) Making recombinant proteins in animals—different systems, different applications. Trends Biotechnol 21:394–399. doi:10.1016/S0167-7799(03)00190-2
Farid SS (2007) Process economics of industrial monoclonal antibody manufacture. J Chromatogr B Analyt Technol Biomed Life Sci 848:8–18. doi:10.1016/j.jchromb.2006.07.037
Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ et al (1994) Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genet 7:13–21. doi:10.1038/ng0594-13
Hamilton SR, Davidson RC, Sethuraman N, Nett JH, Jiang Y, Rios S et al (2006) Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313:1441–1443. doi:10.1126/science.1130256
Hammer RE, Pursel VG, Rexroad CE Jr, Wall RJ, Bolt DJ, Ebert KM et al (1985) Production of transgenic rabbits, sheep and pigs by microinjection. Nature 315:680–683. doi:10.1038/315680a0
Hanna J, Markoulaki S, Schorderet P, Carey BW, Beard C, Wernig M et al (2008) Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 133:250–264. doi:10.1016/j.cell.2008.03.028
Heyman Y (2005) Nuclear transfer: a new tool for reproductive biotechnology in cattle. Reprod Nutr Dev 45:353–361. doi:10.1051/rnd:2005026
Hofmann A, Kessler B, Ewerling S, Weppert M, Vogg B, Ludwig H et al (2003) Efficient transgenesis in farm animals by lentiviral vectors. EMBO Rep 4:1054–1060. doi:10.1038/sj.embor.7400007
Irie A, Koyama S, Kozutsumi Y, Kawasaki T, Suzuki A (1998) The molecular basis for the absence of N-glycolylneuraminic acid in humans. J Biol Chem 273:15866–15871. doi:10.1074/jbc.273.25.15866
Kaiser J (2008) Is the drought over for pharming? Science 320:473–475. doi:10.1126/science.320.5875.473
Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497. doi:10.1038/256495a0
Kuroiwa Y, Kasinathan P, Choi YJ, Naeem R, Tomizuka K, Sullivan EJ et al (2002) Cloned transchromosomic calves producing human immunoglobulin. Nat Biotechnol 20:889–894. doi:10.1038/nbt727
Kuroiwa Y, Kasinathan P, Matsushita H, Sathiyaselan J, Sullivan EJ, Kakitani M et al (2004) Sequential targeting of the genes encoding immunoglobulin-mu and prion protein in cattle. Nat Genet 36:775–780. doi:10.1038/ng1373
Lathe R, Clarke AJ, Archibald AL, Bishop JO, Simons P, Wilmut I (1986) Novel products from livestock. In: Smith C, King J, Mckay J (eds) Exploiting new technologies in animal breeding: genetic developments. Clarendon Press, Oxford, pp 91–102
Lawrence S (2007) Billion dollar babies—biotech drugs as blockbusters. Nat Biotechnol 25:380–382. doi:10.1038/nbt0407-380
Ledford H (2006) The farmyard drug store. Nature 443:16–17. doi:10.1038/443733a
Lillico SG, Sherman A, McGrew MJ, Robertson CD, Smith J, Haslam C et al (2007) Oviduct-specific expression of two therapeutic proteins in transgenic hens. Proc Natl Acad Sci USA 104:1771–1776. doi:10.1073/pnas.0610401104
Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR et al (1994) Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368:856–859. doi:10.1038/368856a0
McCreath KJ, Howcroft J, Campbell KHS, Colman A, Schnieke AE, Kind AJ (2000) Production of gene-targeted sheep by nuclear transfer from cultured somatic cells. Nature 405:1066–1069. doi:10.1038/35016604
Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448:313–317. doi:10.1038/nature05934
Sang H (2006) Transgenesis sunny-side up. Nat Biotechnol 24:955–956. doi:10.1038/nbt0806-955
Schmidt C (2006) Belated approval of first recombinant protein from animal. Nat Biotechnol 24:877. doi:10.1038/nbt0806-877
Schnieke AE, Kind AJ, Ritchie WA, Mycock K, Scott AR, Ritchie M et al (1997) Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science 278:2130–2133. doi:10.1126/science.278.5346.2130
Schultz WB (1995) Interim definition and elimination of lot-by-lot release for well-characterized therapeutic recombinant DNA-derived and monoclonal antibody biotechnology products. US Fed Reg 60:63048–63049
Sinha U, Hancock TE, Nzerem JJ, Lin PH, Tomlinson JE, Wolf DL (1994) Effect of gamma carboxylation on prothrombinase inhibitory activity of catalytically inactive factor XA. Thromb Res 75:427–436. doi:10.1016/0049-3848(94)90258-5
Subramanian A, Paleyanda RK, Lubon H, Williams BL, Gwazdauskas FC, Knight JW et al (1996) Rate limitations in posttranslational processing by the mammary gland of transgenic animals. Ann N Y Acad Sci 782:87–96. doi:10.1111/j.1749-6632.1996.tb40550.x
Tomizuka K, Shinohara T, Yoshida H, Uejima H, Ohguma A, Tanaka S et al (2000) Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci USA 97:722–727. doi:10.1073/pnas.97.2.722
Walsh G (2006) Biopharmaceutical benchmarks 2006. Nat Biotechnol 24:769–776. doi:10.1038/nbt0706-769
Whitelaw CB, Radcliffe PA, Ritchie WA, Carlisle A, Ellard FM, Pena RN et al (2004) Efficient generation of transgenic pigs using equine infectious anaemia virus (EIAV) derived vector. FEBS Lett 571:233–236. doi:10.1016/j.febslet.2004.06.076
Wildt S, Gerngross TU (2005) The humanization of N-glycosylation pathways in yeast. Nat Rev Microbiol 3:119–128. doi:10.1038/nrmicro1087
Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH (1997) Viable offspring derived from fetal and adult mammalian cells. Nature 385:810–813. doi:10.1038/385810a0
Yasunaga H (2007) Risk of authoritarianism: fibrinogen-transmitted hepatitis C in Japan. Lancet 370:2063–2067. doi:10.1016/S0140-6736(07)61867-4
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kind, A., Schnieke, A. Animal pharming, two decades on. Transgenic Res 17, 1025–1033 (2008). https://doi.org/10.1007/s11248-008-9206-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11248-008-9206-3